Immune Thrombocytopenic Purpura (ITP) – CVAY736Q12301

The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.

Key Inclusion criteria

• Male or female patients aged 18 years and older on the day of signing the informed consent.
• A diagnosis of primary ITP, with insufficient response to, or relapse after a first-line corticosteroid therapy ± IVIG.
• Patient with platelet count <30G/L (whom eltrombopag is clinically indicated as per physician’s discretion) and with no contraindication to receive eltrombopag
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.